Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.
作者信息
Barre J, Houin G, Rosenbaum J, Zini R, Dhumeaux D, Tillement J P
出版信息
Br J Clin Pharmacol. 1984 Oct;18(4):652-3. doi: 10.1111/j.1365-2125.1984.tb02525.x.
Abstract
摘要
相似文献
1
Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.肝硬化患者α1-酸性糖蛋白降低：对药物蛋白结合的影响
Br J Clin Pharmacol. 1984 Oct;18(4):652-3. doi: 10.1111/j.1365-2125.1984.tb02525.x.
2
[Serum alpha 1-acid glycoprotein in the biologic diagnosis of hepatic cirrhosis].[血清α1-酸性糖蛋白在肝硬化生物学诊断中的应用]
Rev Clin Esp. 1984 Mar 31;172(6):333-5.
3
Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.肝硬化的严重程度以及α1-酸性糖蛋白浓度与利多卡因血浆蛋白结合的关系。
Clin Pharmacol Ther. 1990 Mar;47(3):366-70. doi: 10.1038/clpt.1990.41.
4
Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs.肾病或肝病患者、新生儿及健康受试者中白蛋白和α-1-酸性糖蛋白浓度的个体间差异：对药物结合的影响。
Int J Clin Pharmacol Ther Toxicol. 1992 Apr;30(4):128-33.
5
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.严重肝硬化患者中红霉素的药代动力学。血清结合力降低和肝脏代谢能力受损的各自影响。
Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x.
6
7
Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis.α1-酸性糖蛋白浓度与分子异质性：与健康志愿者、肺癌患者或肝硬化患者血清中氧烯洛尔结合的关系。
Br J Clin Pharmacol. 1988 Jun;25(6):733-40. doi: 10.1111/j.1365-2125.1988.tb05260.x.
8
Hyperfucosylation of alpha 1-acid glycoprotein during cirrhosis.肝硬化期间α1-酸性糖蛋白的高岩藻糖基化
Prog Clin Biol Res. 1989;300:215-8.
9
Glycosylation change of alpha-1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis.α-1-酸性糖蛋白的糖基化变化作为肝细胞癌和肝硬化的血清生物标志物。
Biomark Med. 2017 May;11(5):423-430. doi: 10.2217/bmm-2016-0284.
引用本文的文献
1
Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study.女性中α-1酸性糖蛋白与肝脂肪变性和肝纤维化的关联：一项基于人群的研究。
BMC Gastroenterol. 2025 Aug 16;25(1):587. doi: 10.1186/s12876-025-04212-3.
2
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial.fedratinib在中度和重度肝功能损害成人患者中的药代动力学、安全性和耐受性：1期FEDR-CP-001试验结果
Cancer Chemother Pharmacol. 2025 Jul 2;95(1):65. doi: 10.1007/s00280-025-04785-6.
3
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.索替司他在轻度或中度肝损伤或正常肝功能参与者中的 1 期药代动力学和安全性研究。
Pharmacol Res Perspect. 2024 Aug;12(4):e1213. doi: 10.1002/prp2.1213.
4
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.肝硬化对新型双重食欲素受体拮抗剂达力雷汀的药代动力学、代谢和耐受性的影响。
Clin Pharmacokinet. 2021 Oct;60(10):1349-1360. doi: 10.1007/s40262-021-01028-8. Epub 2021 May 18.
5
Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.年龄、肾肝功能损害对利培酮人体药代动力学的影响。
Psychopharmacology (Berl). 1995 Dec;122(3):223-9. doi: 10.1007/BF02246543.
6
Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.肾功能和肝功能减退患者血清中丙吡胺的定量和定性结合特性。
Br J Clin Pharmacol. 1987 Jan;23(1):41-6. doi: 10.1111/j.1365-2125.1987.tb03007.x.
7
The plasma protein binding of basic drugs.碱性药物的血浆蛋白结合情况。
Br J Clin Pharmacol. 1986 Nov;22(5):499-506. doi: 10.1111/j.1365-2125.1986.tb02927.x.
8
Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.在与α1-酸性糖蛋白浓度升高相关的疾病状态下，卡马西平的血清蛋白结合发生改变。
Eur J Clin Pharmacol. 1986;31(1):85-9. doi: 10.1007/BF00870992.
9
Kinetics of disopyramide in decreased hepatic function.肝功能减退时丙吡胺的药代动力学
Eur J Clin Pharmacol. 1986;31(1):73-7. doi: 10.1007/BF00870990.
10
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.严重肝硬化患者中红霉素的药代动力学。血清结合力降低和肝脏代谢能力受损的各自影响。
Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x.
本文引用的文献
1
Intersubject and dose-related variability after intravenous administration of erythromycin.静脉注射红霉素后的个体间差异及剂量相关变异性。
Br J Clin Pharmacol. 1980 Sep;10(3):273-9. doi: 10.1111/j.1365-2125.1980.tb01755.x.
2
Measurement of serum alpha 1-acid glycoprotein and alpha 1-antitrypsin desialylation in liver disease.肝脏疾病中血清α1-酸性糖蛋白及α1-抗胰蛋白酶去唾液酸化的测定
Hepatology. 1983 May-Jun;3(3):356-9. doi: 10.1002/hep.1840030313.
3
Disease-induced changes in the plasma binding of basic drugs.疾病引起的碱性药物血浆结合变化。
Clin Pharmacokinet. 1980 May-Jun;5(3):246-62. doi: 10.2165/00003088-198005030-00004.
4
Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma.
Cancer. 1979 Feb;43(2):596-604. doi: 10.1002/1097-0142(197902)43:2<596::aid-cncr2820430229>3.0.co;2-r.
5
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.
N Engl J Med. 1978 Dec 28;299(26):1435-9. doi: 10.1056/NEJM197812282992604.
Zotero 插件